The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects.
Department of Otorhinolaryngology, Head and Neck Surgery, University of Maryland School of Medicine, Baltimore, Maryland 21201-1619, USA. firstname.lastname@example.org
The oncologist 2007;12(9):1084-95.
Several monoclonal antibodies are now in clinical use for cancer therapy, and many others are currently undergoing clinical evaluation. These agents offer unique specificity against key molecular targets on tumor cells or in the tumor microenvironment. The clinical efficacy of monoclonal antibodies is generally attributed to target-specific mechanisms resulting from neutralizing or inhibiting a growth factor or receptor that drives cell proliferation and tumor growth. Several targets, including CD20, human epidermal growth factor receptor 2, vascular endothelial growth factor, and epidermal growth factor receptor, have been validated in specific malignancies on the basis of monoclonal antibody efficacy. However, monoclonal antibodies also have the potential to activate immune-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. These functions result from interactions involving the Fc domain of the antibody, and, consequently, may vary by antibody, isotype, and Fc modification, such as changes in glycosylation. Accordingly, all monoclonal antibodies directed against a given target should not be considered equivalent in their ability to stimulate immune-mediated effector functions.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
R Adler; J C Glorioso; J Cossman; M LevineInfection and immunity 1978;21(2):442-7.
T Aoki; C Hamada; S Ohno; H Miyakoshi; Y Kaneko; M Robert-Guroff; R C Ting; R C GalloHaematology and blood transfusion 1985;29():342-4.
A Azimzadeh; H Watier; C Meyer; J M Guillaumin; J P Beller; R Kieny; P Zibolt; K Boudjema; D Jaeck; J Cinqualbre; et al.Transplantation proceedings 1997;29(5):2385-6.
Appears in this Publication
Author of this Publication